Ionis Pharmaceuticals (IONS) FCF Margin (2009 - 2026)

Ionis Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 331.01% for Q1 2026.

• In Q1 2026, FCF Margin fell 20689.0% year-over-year to 331.01%; the TTM figure through Mar 2026 stood at 159.71% (down 8231.0% YoY), while the FY2025 annual figure was 33.91%, up 4355.0% from the prior year.
• FCF Margin was 331.01% for Q1 2026 at Ionis Pharmaceuticals, down from 78.2% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 6951.65% in Q2 2025 to a low of 331.01% in Q1 2026.
• Historically, FCF Margin has averaged 327.59% across 5 years, with a median of 77.09% in 2023.
• The sharpest annual moves came in 2025 and 2026: FCF Margin soared 700764 bps in 2025, then plunged 20689 bps in 2026.
• A 5-year view of FCF Margin shows it stood at 134.53% in 2022, then surged by 113 bps to 17.66% in 2023, then sank by 454 bps to 62.51% in 2024, then fell by 25 bps to 78.2% in 2025, then slumped by 323 bps to 331.01% in 2026.
• The last three FCF Margin figures came in at 331.01% (Q1 2026), 78.2% (Q4 2025), and 87.23% (Q3 2025), per Business Quant data.